Philip Voyias | Author | SciTechnol | Endocrinology & Diabetes R

Philip Voyias Author

mkhin@rcog.org.uk +44 20 7772 6484 | +44 20 7772

Subjects of specialization
Metformin, Vitamin B12, Liver cells, HepG2 culture

Affiliation
Population Evidence and Technologies, Warwick Medical School, University of Warwick, Coventry, United Kingdom

Biography

Philip Voyias Population Evidence and Technologies, Warwick Medical School, University of Warwick, Coventry, United Kingdom.His publications include: 1.de Jager JA, Kooy P, Lehert MG, Wulffele J, van der KD, et al. (2010) Long term treatment with metformin in patients with type 2 diabetes and risk of vitamin B-12 deficiency: Randomised placebo controlled trial. BMJ 340: 2181. 2.Reinstatler LP, Qi RS, Williamson JV, Garn JP, Jr Oakley, et al. (2012) Association of biochemical B(1)(2) deficiency with metformin therapy and vitamin B (1) (2) supplements: The National Health and Nutrition Examination Survey 1999-2006. Diabetes Care 35: 327-333.

Publications

Research Article Open Access

Efficacy of Metformin in Vitamin B12 Deficient Liver Cells

Author(s):

May Oo Khin, Antonysunil Adaikalakoteswari, Philip Voyias, Ponnusamy Saravanan

Objective: The anti-diabetic drug, metformin, is associated with progressive decrease in serum vitamin B12 levels whereas vitamin B12 deficiency is related to increased insulin resistance and dyslipidaemia by altered methylation. As the risk of vitamin B12 deficiency is increased among metformin users, it is of utmost importance to examine how metformin response in vitamin B12 deficient population.

Research design and methods: We investigated the cellular mechanism of metformin in vitamin B12 insufficient human hepatocellular cell line (HepG2). HepG2 was cultured in different vitamin B12 conditions (0, 10, 100, 1000 nM) for four passages over 24 days. Then, they were treated with metformin 2 mM for 24 h. Protein and RNA extracts were quantified ... view more»

Abstract HTML PDF